ESSA Pharma Inc., a pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate cancer, announced today the receipt of a $1.2 million payment from the Cancer Prevention Research Institute of Texas.
FDA granted regular approval to Tagrisso (osimertinib) for the treatment of patients with metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer, as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor therapy.
FDA approved Zejula (niraparib), a poly ADP-ribose polymerase inhibitor, for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
Gamida Cell announced that orphan drug designation has been granted by the European Medicines Agency's Committee for Orphan Medicinal Products regarding NiCord as a treatment for haematopoietic stem cell transplantation, also commonly known as bone marrow transplantation.
Cota Healthcare announced the signing of a multi-year collaboration with Novartis Pharmaceuticals Corp. to help improve clinical and cost outcomes for breast cancer patients.
Novartis said FDA has accepted the company's Biologics License Application filing and granted priority review for CTL019 (tisagenlecleucel-T), an investigational chimeric antigen receptor T cell therapy, in relapsed and refractory pediatric and young adult patients with B-cell acute lymphoblastic leukemia.
BMS and Foundation Medicine announced a collaboration that leverages Foundation Medicine's comprehensive genomic profiling and molecular information solutions to identify predictive biomarkers such as Tumor Mutational Burden and Microsatellite Instability in patients enrolled across clinical trials investigating Bristol-Myers Squibb's cancer immunotherapies.
AbbVie and M2Gen said AbbVie has joined the Oncology Research Information Exchange Network Avatar Research Program.
FDA granted an accelerated approval to Bavencio (avelumab) for the treatment of patients 12 years and older with metastatic Merkel cell carcinoma.
FDA granted an accelerated approval to Bavencio (avelumab) for the treatment of patients 12 years and older with metastatic Merkel cell carcinoma.